Chimeric Antigen Receptor T Cells Targeting Glypican-3

NCT03884751 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
9
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

CARsgen Therapeutics Co., Ltd.

Collaborators